Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Sarepta Therapeutics Inc banner

Sarepta Therapeutics Inc
LSE:0L35

Watchlist Manager
Sarepta Therapeutics Inc Logo
Sarepta Therapeutics Inc
LSE:0L35
Watchlist
Price: 16.7 USD 2.14%
Market Cap: $136B
Write Note Create Alert Ask AI

Wall St Price Targets

0L35 Price Targets Summary
Sarepta Therapeutics Inc

Wall Street analysts forecast 0L35 stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for 0L35 is 23.34 USD with a low forecast of 5.11 USD and a high forecast of 40.41 USD.

0L35 Lowest Forecast
Wall Street Target
$5.11
-69% Downside
0L35 Average Forecast
Wall Street Target
$23.34
40% Upside
0L35 Highest Forecast
Wall Street Target
$40.41
142% Upside
Lowest Forecast
Price Target
5.11 USD
69% Downside
Average Forecast
Price Target
23.34 USD
40% Upside
Highest Forecast
Price Target
40.41 USD
142% Upside
Sarepta Therapeutics Inc Competitors:
Price Targets
INBK
First Internet Bancorp
5% Upside
ACAD
ACADIA Pharmaceuticals Inc
16% Upside
FAST
Fastenal Co
-4% Downside
INBK
First Internet Bancorp
5% Upside
ACAD
ACADIA Pharmaceuticals Inc
16% Upside
FAST
Fastenal Co
-4% Downside

Revenue
Forecast

37% / Year
Past Growth
-4% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
37% / Year
Past Growth
-4% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 37%. The projected CAGR for the next 8 years is -4%.

What are analyst estimates?

Gross Profit
Forecast

N/A
Past Growth
-2% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
N/A
Past Growth
-2% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

The compound annual growth rate for Gross Profit over the next 8 years is -2%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
2%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
2%
Average Beat

What are analyst estimates?

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
4%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
4%
Average Beat

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
5%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
5%
Average Beat

What are analyst estimates?

Continue 0L35 Research

Summary
0L35 intrinsic value, competitors valuation, and company profile.
DCF Valuation
0L35 stock valuation using Discount Cash Flow valuation method.
Relative Valuation
0L35 stock valuation using valuation multiples.
Wall St Estimates
0L35 price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
0L35 stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Sarepta Therapeutics Inc listings:
NASDAQ • USD
SRPT
 F • EUR
AB3A
 XBER • EUR
AB3A
 XMUN • EUR
AB3A
 SWB • EUR
AB3A
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is 0L35's stock price target?
Price Target
23.34 USD

According to Wall Street analysts, the average 1-year price target for 0L35 is 23.34 USD with a low forecast of 5.11 USD and a high forecast of 40.41 USD.

What is the Revenue forecast for Sarepta Therapeutics Inc?
Projected CAGR
-4%

Over the last 13 years, the compound annual growth rate for Revenue has been 37%. The projected CAGR for the next 8 years is -4%.

What is the Gross Profit forecast for Sarepta Therapeutics Inc?
Projected CAGR
-2%

The compound annual growth rate for Gross Profit over the next 8 years is -2%.

Back to Top
ALPHA SPREAD
Follow us
Join 351,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett